实用心脑肺血管病杂志
實用心腦肺血管病雜誌
실용심뇌폐혈관병잡지
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
2015年
10期
58-60
,共3页
心力衰竭%瑞舒伐他汀%治疗结果%内皮素%炎性因子
心力衰竭%瑞舒伐他汀%治療結果%內皮素%炎性因子
심력쇠갈%서서벌타정%치료결과%내피소%염성인자
Heart failure%Rosuvastatin%Treatment outcome%Endothelin%Inflammatory cytokines
目的：探讨瑞舒伐他汀治疗慢性心力衰竭的临床疗效及其对内皮素和炎性因子的影响。方法选择2013年5月—2014年11月榆林市星元医院收治的慢性心力衰竭患者106例，随机分为治疗组和对照组，各53例。对照组患者采用常规对症治疗，治疗组患者在对照组基础上给予瑞舒伐他汀治疗，两组患者疗程均为12周。比较两组患者治疗12周后临床疗效，治疗前后心率（HR）、左心室射血分数（LVEF）、左心室内压（LVP）及血浆内皮素、血清炎性因子〔白介素6（IL -6）、肿瘤坏死因子α（TNF -α）〕水平，并观察治疗期间不良反应发生情况。结果治疗组患者临床疗效优于对照组（P ﹤0.05）。治疗前两组患者 HR、LVEF 及 LVP 比较，差异无统计学意义（ P ﹥0.05）；治疗后治疗组患者 LVEF 高于对照组，HR、LVP 低于对照组（P ﹤0.05）。治疗前两组患者血浆内皮素及血清 IL -6、TNF -α水平比较，差异无统计学意义（P ﹥0.05）；治疗后治疗组患者血浆内皮素及血清 IL -6、TNF -α水平低于对照组（P ﹤0.05）。两组患者治疗期间均未出现明显不良反应。结论瑞舒伐他汀治疗慢性心力衰竭的临床疗效确切，能明显降低患者内皮素及炎性因子水平，进而改善血管内皮细胞功能，减轻炎性反应。
目的：探討瑞舒伐他汀治療慢性心力衰竭的臨床療效及其對內皮素和炎性因子的影響。方法選擇2013年5月—2014年11月榆林市星元醫院收治的慢性心力衰竭患者106例，隨機分為治療組和對照組，各53例。對照組患者採用常規對癥治療，治療組患者在對照組基礎上給予瑞舒伐他汀治療，兩組患者療程均為12週。比較兩組患者治療12週後臨床療效，治療前後心率（HR）、左心室射血分數（LVEF）、左心室內壓（LVP）及血漿內皮素、血清炎性因子〔白介素6（IL -6）、腫瘤壞死因子α（TNF -α）〕水平，併觀察治療期間不良反應髮生情況。結果治療組患者臨床療效優于對照組（P ﹤0.05）。治療前兩組患者 HR、LVEF 及 LVP 比較，差異無統計學意義（ P ﹥0.05）；治療後治療組患者 LVEF 高于對照組，HR、LVP 低于對照組（P ﹤0.05）。治療前兩組患者血漿內皮素及血清 IL -6、TNF -α水平比較，差異無統計學意義（P ﹥0.05）；治療後治療組患者血漿內皮素及血清 IL -6、TNF -α水平低于對照組（P ﹤0.05）。兩組患者治療期間均未齣現明顯不良反應。結論瑞舒伐他汀治療慢性心力衰竭的臨床療效確切，能明顯降低患者內皮素及炎性因子水平，進而改善血管內皮細胞功能，減輕炎性反應。
목적：탐토서서벌타정치료만성심력쇠갈적림상료효급기대내피소화염성인자적영향。방법선택2013년5월—2014년11월유림시성원의원수치적만성심력쇠갈환자106례，수궤분위치료조화대조조，각53례。대조조환자채용상규대증치료，치료조환자재대조조기출상급여서서벌타정치료，량조환자료정균위12주。비교량조환자치료12주후림상료효，치료전후심솔（HR）、좌심실사혈분수（LVEF）、좌심실내압（LVP）급혈장내피소、혈청염성인자〔백개소6（IL -6）、종류배사인자α（TNF -α）〕수평，병관찰치료기간불량반응발생정황。결과치료조환자림상료효우우대조조（P ﹤0.05）。치료전량조환자 HR、LVEF 급 LVP 비교，차이무통계학의의（ P ﹥0.05）；치료후치료조환자 LVEF 고우대조조，HR、LVP 저우대조조（P ﹤0.05）。치료전량조환자혈장내피소급혈청 IL -6、TNF -α수평비교，차이무통계학의의（P ﹥0.05）；치료후치료조환자혈장내피소급혈청 IL -6、TNF -α수평저우대조조（P ﹤0.05）。량조환자치료기간균미출현명현불량반응。결론서서벌타정치료만성심력쇠갈적림상료효학절，능명현강저환자내피소급염성인자수평，진이개선혈관내피세포공능，감경염성반응。
Objective To investigate the clinical effect of rosuvastatin on chronic heart failure and its impact on endothelin and inflammatory cytokines. Methods A total of 106 patients with chronic heart failure were selected in Xingyuan Hospital of Yulin from May 2013 to November 2014,and they were randomly divided into control group and treatment group, each of 53 cases. Patients of both groups were given conventional symptomatic treatment,while patients of treatment group were given extra rosuvastatin;both groups treated for 12 weeks. Clinical effect,heart rate,LVEF,LVP,plasma endothelin level, serum levels of IL - 6 and TNF - α before and after treatment were compared between the two groups,and the incidence of adverse reactions during treatment was observed. Results The clinical effect of treatment group was statistically significantly better than that of control group( P ﹤ 0. 05). No statistically significant differences of heart rate,LVEF or LVP was found between the two groups before treatment( P ﹥ 0. 05);after treatment,LVEF of treatment group was statistically significantly higher than that of control group,while heart rate and LVP of treatment group were statistically significantly lower than those of control group(P ﹤ 0. 05). No statistically significant differences of plasma endothelin level,serum levels of IL - 6 or TNF - αwas found between the two groups before treatment(P ﹥ 0. 05);while plasma endothelin level,serum levels of IL - 6 and TNF- α of treatment group were statistically significantly lower than those of control group after treatment(P ﹤ 0. 05). No one of the two groups occurred any obvious adverse reactions during treatment. Conclusion Rosuvastatin has certain clinical effect in treating chronic heart failure,can effectively improve the vascular endothelial function,relieve the inflammatory reaction.
